Legend Biotech Corp LEGN
Annual
Quarterly
FY2025 · ended Dec 31, 2025 · Revenue $1.03B, +64.0% YoY · Filed Mar 10, 2026
Legend Biotech Corp (LEGN) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $1.0 billion and a net loss of $296.8 million. Free cash flow was -$128.8 million. As of Dec 31, 2025 it held $901.9 million in cash and investments and $413.7 million in total debt.
Revenue
$1.03B
+64.0% vs prior year
Net income
$-296.80M
-67.7% vs prior year
Operating cash flow
$-100.20M
+30.4% vs prior year
Free cash flow
$-128.80M
+18.5% vs prior year
EPS
$-0.81
-68.8% vs prior year
Dividend per share
None
Shares outstanding
369.89M
+0.7% vs prior year
Net cash
$488.20M
FY 2025
Operating margin
-13.3%
FY 2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LEGN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Cayman Islands
- Headquarters
- Somerset, NJ
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1801198
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $1.0B | $627.3M | $285.1M | $50.3M | $68.8M |
| Operating income | -$136.5M | — | — | — | — |
| Net income | -$296.8M | -$177.0M | -$518.3M | -$446.3M | -$403.6M |
| Diluted EPS | -$0.81 | -$0.48 | -$1.47 | -$1.40 | -$1.43 |
| Operating cash flow | -$100.2M | -$144.0M | -$393.3M | -$201.3M | -$198.5M |
| Free cash flow | -$128.8M | -$158.1M | -$413.4M | -$222.2M | -$240.7M |
| Total assets | $1.7B | $1.7B | $1.8B | $1.3B | $1.1B |
| Total liabilities | $731.6M | $629.6M | $597.2M | $586.7M | $353.5M |
| Stockholders' equity | $1.0B | $1.0B | $1.3B | $744.4M | $765.9M |
| Cash and investments | $901.9M | $286.7M | $1.3B | $786.0M | $688.9M |
| Total debt | $413.7M | $299.4M | $297.3M | $273.6M | $122.2M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Nov 4, 2026 | Nov 3, 2026 |
| 6-K | Current report (foreign issuer) | Oct 15, 2026 | Oct 15, 2026 |
| 6-K | Current report (foreign issuer) | Oct 13, 2026 | Oct 13, 2026 |
| 6-K | Current report (foreign issuer) | Sep 25, 2026 | Sep 24, 2026 |
| 6-K | Current report (foreign issuer) | Sep 24, 2026 | Sep 24, 2026 |
| 6-K | Current report (foreign issuer) | Sep 15, 2026 | Sep 15, 2026 |
All 385 Legend Biotech Corp SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.